Pediatric

Of both lineages Table 2 ; . by dual-color immunofluorescence. Strated that more than one third of all adults with ITP had inadequate platelet production despite increased megakaryocyte numbers in the bone marrow.16-18 It was assumed that autoantibody interfered with platelet formation or egress from the marrow space. A number of studies ultimately confirmed this hypothesis with both in vitro and in vivo platelet production studies.19-22 Like adults, certain pediatric patients also demonstrate decreased megakaryocytopoiesis in the presence of ITP plasma containing anti-GPIb-IX autoantibodies alone or in combination with IIb-IIIa GPIIb-IIIa ; autoantibodies, in vitro compared to control normal AB plasma Figure 1; see Color Figures, page 516 ; .21, 22 However, those children with ITP mediated by platelet autoantibodies directed against other epitopes unknown antibody group in Figure 1; see Color Figures, page 516 ; , demonstrated little or no suppression. Furthermore, those pediatric patients with IIb-IIIa GPIIb-IIIa ; autoantibodies alone demonstrated a mixed response, with certain plasmas being highly suppressive, while others actually appeared to stimulate growth. McMillan et al recently demonstrated that autoantibody suppression of megakaryocytes by autoantibody may be associated with increased apoptosis.22 This was not observed in the pediatric ITP megakaryocytopoiesis studies, despite similar autoantibody specificities.23 It is possible that lymphocyte signaling, receptor occupancy and clustering may also play a more critical role in triggering megakaryocyte apoptosis in the adults. Alternatively, antiplatelet autoantibodies in childhood ITP may not recognize the same epitopes on target molecules, nor have the same affinity and complement binding capacity due to a less mature immune system. Adolescent ITP patients are much more likely to have anti-GPIb autoantibodies and have a clinical course similar to that of the adult with ITP. The disparities in suppression of megakaryocytopoiesis observed between adult and pediatric ITP patients reinforces the growing evidence that the immunologic trigger, course and outcome for children with immune mediated thrombocytopenia is quite different than that of adults. Treatment Options in Childhood ITP Pediatric hematologists must consider a number of factors when considering the management of a child with ITP.4, 24-30 In the absence of hemorrhage, the child with scattered petechiae and superficial bruising may only warrant close observation, as long as the parents are informed of the risks associated with severe thrombocytopenia and can rapidly return to the hospital should bleeding occur. If the family is geographically isolated or unable to closely observe their child, treatment to increase the platelet count above 20, 000 and shorten the duration of thrombocytopenia should be considered.31 Most common treatment options are listed in Table 3. If the decision is made to treat a child with ITP, the most common approach would include either IVIG, anti-D immunoglobulin in the Rh + patient, or steroids once one is 99.

Adult dose 1 gtt in affected eye s ; bid pediatric dose not established contraindications documented hypersensitivity; bronchial asthma; severe copd; sinus bradycardia; second- and third-degree av block; overt cardiac failure; cardiogenic shock interactions may have additive systemic effects if patient is already on systemic beta-blockers pregnancy c - safety for use during pregnancy has not been established. HUP-Department of Surgery 3400 Spruce St 4 Silverstein Bldg Philadelphia, PA 19104 215 ; 662-2050 Omaida C. Velazquez, MD HUP-Division of Organ Transplantation 3400 Spruce St 4 Silversteing Bldg Philadelphia, PA 19104 215 ; 662-2050 Clyde F. Barker, MD HUP-Division of Vascular Surgery 3400 Spruce St Philadelphia, PA 19104 215 ; 662-2050 Jeffrey P. Carpenter, MD Ronald M. Fairman, MD Michael Golden, MD Marc E. Mitchell, MD Omaida C. Velazquez, MD and pegasys.

Summarized in Table A1. The reference numbers of the different connections in column 1 of Table A1 correspond with those in Fig. 3. The area of connectivity for each connection type was determined by the destination area around the cell and the hole in the destination area that was excluded from making synaptic contacts columns 24, Table A1 ; . In this destination area, the probability for a synapse to occur declined exponentially with horizontal distance between source presynaptic ; and target postsynaptic ; cells Probability and Exponential in Table A1 ; . The conduction velocity of the connection and neuronal interdistance determined the delay between spike generation and synaptic effect column 7, Table A1 ; . Synaptic conductance was determined by a dual exponential function and maximum conductance gmax. In the network gmax was weighed with a factor W, which was determined by the distance between source and target neurons according to the exponential function: W max W min W ; exp d 3D ; , where max W, min W, and the spatial three-dimensional constant 3D are summarized in the last three columns of Table A1.
PETNET Solutions Petrochem Valve Inc. Ms. June Pettus Mr. Elliott Pew Mr. David P. Pfeil PFI Constructors, Inc. Pfizer Foundation, Inc. Pfizer, Inc. Ms. Marjorie L. Pflaum Pharmion Corporation Mr. William J. Phelan Phelps Dodge Foundation Phi Beta Psi Sorority Phi Delta Theta Foundation Philips Medical Systems Philips Medical Systems North America Co. Mr. Alan M. Phillips Mr. and Mrs. David Phillips Ms. Jennie L. Phillips The Waite and Genevieve Phillips Foundation Phoenix Biotechnology, Inc. Physicians Education Resource, L.P. Physicians World Mr. Robert S. Pickelner Mr. and Mrs. Jim B. Pickens Dr. and Mrs. Glynn John Pickens Mr. and Mrs. Robert H. Pickens Piedra Capital, Ltd. Ed and H. Pillsbury Foundation Harriet Pillsbury Foundation Pinnacle Polymers Mrs. Charlotte Pippin Pitch and Putt For A Cure Mr. James D. Pitcock, Jr. Dr. Carl Plager Mrs. Madeline C. Plansky Mr. and Mrs. W. Craig Plumhoff William F. Poe Foundation Pogo Producing Company Mr. Karl Pohl Polar-Ray Sunglass, Inc. Polemanakos Foundation Mr. David G. Polis Mrs. Lewis H. Pool Mr. and Mrs. William L. Poole Poongsan America Corporation Mrs. Marjorie M. Postma Mr. David Powers Tim and Katherine Pownell Mr. and Mrs. Richard E. Prasek Mr. and Mrs. G. Heyward Preacher, Jr. Precision Fuels, Inc. Mrs. Sheila Prenowitz Mr. Alex Preston Mr. and Mrs. Richard L. Preston Mr. Carl Price Mr. and Mrs. Lamar Pride Primary Natural Resources, Inc. Professional Datasolutions, Inc. Prostate Cancer Foundation Prudential Foundation William H. Prusoff Foundation Mr. Jessie D. Puckett, Jr and pegfilgrastim.
This resource guide has been funded by the WINNIPEG REGIONAL HEALTH AUTHORITY wrha.mb Search ENCOMPASS to find health services near you. Between 50 and 60 years and 3.4-fold 95% CI 2.94.0 ; among patients aged 60 or more. Factors potentially explaining the late diagnosis of HIV infection in older patients include less common routine screening; poor awareness of the risk of HIV infection or of safer sex practices in this age group; failure of physicians to consider the possibility of HIV infection in these patients; and confusion between symptoms of opportunistic infections and those of frequent co-morbid conditions associated with ageing. In particular, HIV infection itself may mimic neurological disorders such as Alzheimer's disease, Parkinson's disease and cerebrovascular dementia. Internists, general practitioners, geriatricians and neurologists should thus be more aware of the possibility of occult HIV infection among their patients and pegvisomant. While torrents of rain flooded South Hampton Roads and Suffolk area, the rain line held strong protecting dedicated BMW crews that rallied up at the Cheatham Navy Annex picnic area for our 1st Annual Club picnic on 16 June. We stayed dry until the then! Many thanks to the 40 Bimmer and Beemer fanatics that filled the picnic area! Jim from Adventure BMW Motorcycles and 5 of their Beemer crews broke-off from their Saturday breakfast gathering and ride to join us for lunch. Pete 533i ; , our master chef, did his thing, and by the time the rains finally arrived, we were well into desserts and door-prize drawings. A special thanks to all the members that brought the extra desserts, salads and fixins for the picnic. It all was definitely "finger-lickin' good." Roads remained dry in the Williamsburg area as the set-up crews got the picnic grounds ready for the Club. While Jim 318i ; and George 320i ; worked the details with the gate guards and outdoor recreations folks for the club access and the sports equipment, Curt M5 ; , Chess 2002 ; and Brent 325e ; off-loaded the food, and got the place looking like a BMW convention, with flags, banners, and streamers about to complement the blue and white cake we had for dessert that was framed with 2002s, Z3s and anM3. Steve and Laurel 2002 ; brought the drinks cooled and ready to picnic! With cars arriving, and parked throughout the picnic area, you could tell that this was going to be a super time. Yep, we had all the normal picnic stuff, burgers, dogs, beans salads, but more importantly a great time to talk about experiences at different dealers, pros and cons of some aftermarket applications, and then, just some good time to talk. The Beemer crowd recalled several of the rides that they recently completed into the Blue Ridge - and invited the "car guys" to come along next time. They also made the point to remind us that "the BMW motorcycles came first in 1926 then the BMW legendary cars." We had a great time admiring their beautiful cycles! The cast of drivers and cars attending covered several decades, from the early 70s to hot off the production line: Robert 323i ; , Doug 2002 ; , Mark Theresa 318ti AC Schnitzer, 325iC, 633Csi ; , Rick 318is ; , John M635Csi ; , Rick 323i ; , Philip 318is ; , Keith 325iC ; , and Vic BMW seeking ; and John mixed blood Porsche Bimmerhead ; were among the many that made it. To the many wives, friends, and kids that came too-thanks for joining the super die-hard crowd! Pete brought several of the club's special tools - for a grown-ups show and tell. Many members did not know about the tools the club owns - we talked through the uses of each, and how they can be a real time and $$ saver! Additionally, we had several of the past scrap books and plenty of club goodies for sale. Curt ran the door prizes, with several of the Club's polo shirts and T-shirts going, going, gone! As the rains made their way south across the James River you could literally watch the rain clouds approach the picnic area from across the bay ; the crews said their farewells and were on their ways. A great afternoon, despite the gloomy weather picture! We are very fortunate to have a club of real car enthusiasts that love just getting together. Be sure to mark your calendars with our upcoming events. The goal is to provide something for everyone over the course of a quarter. See you on the road! Lastly . the results of the survey that attendees provided at the picnic . thanks to everyone: Events most desired, in priority: 1. Technical sessions. 2. Day drives. 3. Driving Schools. 4. Picnics. 5. Rallys. 6. Autocross. 7. Dinners. 8. Overnighters. With that, we will review the calendar for rest of 2001 .and plans for next year. John had a great idea to visit the PTG racing facility BMWs team ; in the DC area . a great day-drive or overnighter too. Results Histologically, the region of injury was characterized by infiltration of polymorphonuclear leukocytes, the formation of granulation tissue and, iin approximately half the mice, formation of new cartilage Fig. 1 ; . Sixty-four percent of the mice that were operated on showed a definite reactive response between 6 and 8 days, with 44 percent having histologically demonstrable cartilage. In 20 percent of the mice, osteophyte and pemetrexed. Valera Pharmaceuticals Submits NDA for SUPPRELIN-LA, a 12- Month Implant for the Treatment of Central Precocious Puberty Cranbury, N.J., July 6, 2006 Valera Pharmaceuticals, Inc. announced it submitted a New Drug Application NDA ; to the Food and Drug Administration FDA ; for SUPPRELIN R ; -LA, a 12-month implant for central precocious puberty CPP ; , or the early onset of puberty in children. More prevalent in girls, CPP is characterized by the premature development of secondary sexual characteristics in young children due to increased secretion of sex hormones. In addition to social and psychological concerns, the disorder, if left untreated, limits a child from attaining full adult height, thus, resulting in short stature. In November 2005, the FDA granted SUPPRELIN-LA orphan drug designation which provides seven years marketing exclusivity from the date of marketing approval as well as certain economic benefits and tax credits. In addition, Valera noted that SUPPRELIN-LA is the second product to emerge from its pipeline that utilizes its proprietary and patent protected Hydron technology. The first, VANTAS R ; , is a once-per-year implant for advanced prostate cancer which was approved by the FDA in October 2004. This NDA submission marks a major milestone for Valera, said David S. Tierney, M.D., President & CEO. With the potential commercialization of SUPPRELIN-LA in 2007, we anticipate having at least three products on the market next year. In addition to our currently marketed VANTAS, this includes VALSTAR R ; , the only approved drug therapy for certain urinary bladder cancer patients, which we recently acquired and expect to launch around year-end 2006. SUPPRELIN-LA has been designed to provide the continuous 12-month administration of a controlled dose of histrelin, a potent synthetic nonapeptide agonist of naturally occurring gonadotropin-releasing hormone GnRH ; . The standard of care of CPP involves the use of such GnRH agonists to suppress hormonal production to delay the onset of puberty. SUPPRELIN, as a daily injection, was previously approved by the FDA and marketed in the 1990 s to treat CPP. Valera acquired the rights to the brand name earlier this year. The U.S. CPP therapy market is currently estimated at over million annually. The market is dominated by Lupron Depot-PED R ; leuprolide acetate for depot suspension ; from TAP Pharmaceutical Products, Inc. which involves intramuscular injections administered to afflicted children every four weeks. In general, depending on the age of the child at the time of diagnosis, CPP hormonal therapy could run three to five years, or longer. We believe a 12-month implant offers an attractive treatment option for CPP patients, their parents, and the pediatric endocrinologists who treat these children, said Dr. Tierney. Also, from a marketing point of view, SUPPRELIN-LA represents an excellent growth opportunity for Valera, because this therapeutic space is not crowded with competitors and consists of a concentrated physician audience of a few hundred specialists. The multi-center, open-label Phase III study of SUPPRELIN-LA, which is the basis of the NDA submission, involved 36 patients ranging in age from four to eleven years. Sixteen children had received GnRH therapy prior to enrollment while the remaining twenty were nave to treatment. The subcutaneous implant was inserted into the inner aspect of the upper arm. Primary endpoints were hormonal suppression below pubertal levels and continued suppression upon challenge with gonadotropin-releasing hormone. All patients were analyzed for efficacy and safety. The outcome of any FDA review can never be assured, concluded Dr. Tierney. However, we are very encouraged by the clinical data and optimistic about the prospects for SUPPRELIN-LA. About Valera Pharmaceuticals Valera Pharmaceuticals is a specialty pharmaceutical company focused on developing, acquiring, and commercializing products to treat urology and endocrinology diseases and disorders. Utilizing its innovative Hydron technology, Valera is developing soft, compact and flexible hydrogel-based implants which can be designed to release therapeutic agents at a controlled rate for up to twelve months. Additional information about Valera Pharmaceuticals is available at: : valerapharma . This press release contains forward-looking statements that are not historical facts but rather are based on current expectations, estimates and projections about the Company s industry, beliefs and assumptions. Words such as "anticipates, '' "expects, ' "intends, '' "plans, '' "believes, '' "seeks, '' "potential" and "estimates, '' and variations of these words and similar expressions, are intended to identify forward-looking statements. This could produce a rise in neuronal excitability leading to enhanced firing over a time course of hours that might not be detected using a 5-min interstimulus interval. Although we cannot exclude this possibility, we did not observe any cases in which a unit's responses to successively tested chemicals showed a marked increase in firing rate over time. Although capsaicin appeared to induce cross-tachyphylaxis to subsequently tested chemicals, other chemicals did not appear to do so. Even nicotine, which exhibited the most consistent tachyphylaxis in both unit populations, did not show cross-tachyphylaxis in the few cases tested although this requires further verification. Therefore the data indicate that unit responses were not markedly influenced by prior chemicals except capsaicin. Although all corneal-conjunctival units had ipsilateral cutaneous receptive fields, most of the tongue units appeared and pemoline.

Replacement of the ethyl ester with a bioisostere oxazole moiety led to compound 151 scheme 49 ; , which is metabolically stable against esterases, maintains the selectivity and shows increased cdk2 inhibitory potency as well as potent antiproliferative activity in cancer cell lines [7].

Buy cheap Pediatric Pa%n; I., and Gottesman, M. M. 1991 ; Annu. Reu. Med. 42, 277-286 Pelham, H. R. B. 1989 ; Annu. Rev. Cell Biol. 5 , 1-23 Qian, X.-D., and Beck, W. T. 1990 ; Cancer Res. SO, 1132-1137 Raviv, Y., Pollard H. P., Bruggeman E. P., Pastan, I., and Gottesman, M. M. 1990 ; J. Biol. dhem. 265, 3975-3680 Ronlnson, I. B. ed ; 1991 ; Molecular Q I U ~Cellular Bwlo of Multidrug Resista me in Tumor Cells, Plenum Publishing Corporation, %ew York Safa, A. R. 1988 ; Proc. Natl. Acad. SCL. S. A. 8 7187-7191 U. Safa, A. R., Glover, C. J., Meyers, M. B., Biedler, J., and Felsted, R. L. 1987 ; J. Biol. Chem. 262, 7884-7888 Safa, A. R., Mehta, N. D., and Agresti, M. 1989 ; Biochem. Biophys. Res. Commun. 1 6 2 , 1402-1408 Safa, A. R., Stern R. K., Choi, K., Agresti, M., Tamai I., Mehta, N.D., and Roninson, I. B. 11990 ; Proc. Natl. Acad. Sei. U. S. A. 87, 7225-7229 Sanger, F., Nicklen, S., and Coulson, A. R. 1977 ; Proc. Natl. Acad. Scr. U. S. A. 74, 5463-5467 Sarkadi B. Price E. M. Boucher, R.C., Germann, U. A and Scarborough, G. A. 62 ; J. Biol. C&m. 267, 4854-4858 Shimabuku, A. M., Nishimoto, T., Ueda, K., and Komano, T. 1992 ; J. B i Chem. 267, 4308-4311 Tamai, I., and Safa, A. R. 1991 ; J. B i Chem. 266, 16796-16800 Towbin, H., Staehelin, T., and Gordon, J. 1979 ; Proc. Natl. Acad. Sci. U. S. A. 76, 4350-4354 Yang, C.-P. H., Mellado, W., and Horwitz, S. B. 1988 ; Biochem. Pharmacol. 3 7 , 1417-1421 T. Yusa, K., and TSUNO, 1989 ; Cancer Res. 49, 5002-5006 Zubrzycka-Gaarn E., MacDonald, G., Phillips, L., Jorgensen, A. O., and MacLennan, DI H. 1984 ; J. Bzoenerg. Blomembr. 16, 441-446 and penicillamine. Warning section updated regarding the risk of diarrhea, sometimes severe. The median time to first occurrence of grade 2 to 4 diarrhea was 34 days range from 1 to 369 days ; . The median duration of grade 3 seven to nine stools per day or incontinence and malabsorption ; to 4 increase of greater than or equal to 10 stools per day or grossly bloody diarrhea or the need for parenteral support ; diarrhea was 5 days. Warning and drug interaction sections updated regarding the risk of myopathy rhabdomyolysis with telithromycin CYP3A4 inhibition ; and danazol. Postmarketing adverse reactions include increased CPK, elevation in liver transaminases, hepatitis, thrombocytopenia, rhabdomyolysis. Warning regarding individuals who are homozygous for the UGT1A1 * 28 allele being at an increased risk for neutropenia following initiation of Camptosar treatment. Reduction in the initial dose should be considered for patients known to be homozygous for the UGT1A1 * 28 allele. Heterozygous patients carriers of one variant allele and one wild-type allele which results in intermediate UGT1A1 activity ; may be at increased risk for neutropenia. Warning added regarding the risk of neuropsychiatric adverse events ie, somnolence, fatigue, and behavioral abnormalities ; in pediatric patients. Warning and drug interaction sections updated regarding the risk of myopathy rhabdomyolysis with telithromycin CYP3A4 inhibition ; and danazol. Boxed warning regarding atypical presentation of infections during therapy. Warnings regarding the risk of infection and sepsis during therapy. Warning regarding the risk of severe hypotension in individuals whose ability to maintain blood pressure has been compromised ie, blood loss, phenothiazines, general anesthetics ; . Information added to the precaution section regarding risk of leukopenia or neutropenia occurring during therapy. Possible drug interaction with methotrexate that may reduce the renal clearance of methotrexate and increase methotrexate serum concentrations. Active liver disease or unexplained persistent elevations of serum transaminases is a contraindication for use. Rare less than 0.1% ; incidence of myopathy, defined as muscle aching or muscle weakness in conjunction with increases in creatine phosphokinase values to greater than 10 times the upper limit of normal. Warning section updated regarding the risk of metabolic acidosis and cognitive neuropsychiatric adverse events. Updated cardiotoxicity obtained from the National Surgical Adjuvant Breast and Bowel Project NSABP ; study B-31 ; , a randomized, phase 3 trial that was conducted in 2, 043 women with operable, HER2 overexpressing breast cancer IHC 3 + or FISH + ; . This study demonstrated a significant increase in cardiotoxicity in patients who were randomized to the trastuzumab-containing arm as compared to patients who received chemotherapy alone and pediatric. 1. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet. 2000; 355: 165-169. Creutzig U, Ritter J, Vormoor J, et al. Myelodysplasia and acute myelogenous leukemia in Down's syndrome: a report of 40 children of the AML-BFM Study Group. Leukemia. 1996; 10: 1677-1686. Do rdelmann M, Schrappe M, Reiter A, et al. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials: Berlin-Frankfurt-Munster Group. Leukemia. 1998; 12: 645-651. Ragab AH, Abdel-Mageed A, Shuster JJ, et al. Clinical characteristics and treatment outcome of children with acute lymphocytic leukemia and Down's syndrome: a Pediatric Oncology Group study. Cancer. 1991; 67: 1057-1063. Pui CH, Raimondi SC, Borowitz MJ, et al. Immunophenotypes and karyotypes of leukemic cells in children with Down syndrome and acute lymphoblastic leukemia. J Clin Oncol. 1993; 11: 1361-1367. Garre ML, Relling MV, Kalwinsky D, et al. Phar macokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. J Pediatr. 1987; 111: 606-612. Lie SO, Jonmundsson G, Mellander L, Siimes MA, Yssing M, Gustafsson G. A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome: Nordic Society of Paediatric Haematology and Oncology NOPHO ; . Br J Haematol. 1996; 94: 82-88. Lange BJ, Kobrinsky N, Barnard DR, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood. 1998; 91: 608-615. Ravindranath Y, Abella E, Krischer JP, et al. Acute myeloid leukemia AML ; in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood. 1992; 80: 2210-2214. Zipursky A, Thorner P, De HE, Christensen H, Doyle J. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leuk Res. 1994; 18: 163-171. Slrdahl SH, Smeland EB, Holte H, Grnn M, Lie SO, Seip M. Leukemic blasts with markers of four cell lineages in Down's syndrome "megakaryoblastic leukemia" ; . Med Pediatr Oncol. 1993; 21: 254-258. Watson MS, Carroll AJ, Shuster JJ, et al. Trisomy 21 in childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood. 1993; 82: 3098-3102. Glomstein A, Gustafsson G, Clausen N, Saarinen-Pihkala UM, Lie SO. Down's syndrome and acute leukemia in children: a population based Nordic study [abstract]. Leukemia. 1999; 33: 245. Kaspers GJL, Smets LA, Pieters R, Van Zantwijk CH, Van Wering ER, Veerman AJP. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood. 1995; 85: 751-756. Pieters R, Den Boer ML, Durian M, et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia: implications for treatment of infants. Leukemia. 1998; 12: 1344-1348. Zwaan CHM, Kaspers GJL, Pieters R, et al. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood. 2000; 96: 2879-2886. Kaspers GJL, Veerman AJP, Pieters R, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood. 1997; 90: 2723-2729. Asselin BL, Kreissman S, Coppola DJ, et al. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 1999; 21: 6-12. Hongo T, Yajima S, Sakurai M, Horikoshi Y, Hanada R. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood. 1997; 89: 2959-2965. Kaspers GJL, Veerman AJP, Pieters R, et al. Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. Br J Cancer. 1994; 70: 1047-1052. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the FrenchAmerican-British Cooperative Group. Ann Intern Med. 1985; 103: 620-625. Bennett JM, Catovsky D, Daniel MT, et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage M7 ; : a report of the French-American-British Cooperative Group. Ann Intern Med. 1985; 103: 460-462. Pieters R, Loonen AH, Huismans DR, et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood. 1990; 76: 2327-2336. Kaspers GJL, Pieters R, Van Zantwijk CH, et al. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br J Cancer. 1991; 64: 469-474. Rots MG, Pieters R, Kaspers GJL, et al. Differential methotrexate resistance in childhood T- versus common preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay. Blood. 1999; 93: 1067-1074. Taub JW, Huang X, Matherly LH, et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood. 1999; 94: 1393-1400. Taub JW, Stout ML, Buck SA, et al. Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin [letter]. Leukemia. 1997; 11: 1594-1595. Frost BM, Gustafsson G, Larsson R, Nygren P, Lonnerholm G. Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome [letter]. Leukemia. 2000; 14: 943-944. Taub JW, Matherly LH, Stout ML, Buck SA, Gurney JG, Ravindranath Y. Enhanced metabolism of 1 Darabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood. 1996; 87: 3395-3403. Taub JW, Huang X, Ge Y, et al. Cystathionine- synthase cDNA transfection alters the sensitivity and metabolism of 1 D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome. Cancer Res. 2000; 60: 6421-6426. Peled-Kamar M, Lotem M, Okon E, Sachs L, Groner Y. Thymic abnormalities and enhanced apoptosis of thymocytes and bone marrow cells in transgenic mice overexpressing CU Zn-superoxide dismutase: implications for Down syndrome. EMBO J. 1995; 20: 4985-4993. De Haan JB, Wolvetang EJ, Cristiano F, et al. Reactive oxygen species and their contribution to pathology in Down syndrome. Adv Pharmacol. 1997; 38: 379-402. Seidl R, Fang-Kircher S, Bidmon B, Cairns N, Lubec G. Apoptosis-associated proteins p53 and APO-1 Fas CD95 ; in brains of adult patients with Down syndrome. Neurosci Lett. 1999; 260: 9-12. Yasui K, Shinozaki K, Nakazawa T, Agematsu K, Komiyama A. Presenility of granulocytes in Down syndrome individuals. J Med Genet. 1999; 84: 406-412. Ankathil R, Kusumakumary P, Nair MK. Increased levels of mutagen-induced chromosome breakage in Down syndrome children with malignancy. Cancer Genet Cytogenet. 1997; 99: 126-128. Kojima S, Sako M, Kato K, et al. An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome. Leukemia. 2000; 14: 786-791. Belkov BM, Krynetski EY, Schuetz JD, et al. Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood. 1999; 93: 1643-1650. Zhang L, Taub JW, Williamson M, et al. Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: relationship to immunophenotype and ploidy. Clin Cancer Res. 1998; 4: 21692177. Argiris A, Longo GS, Gorlick R, Tong W, Steinherz P, Bertino JR. Increased methotrexate polyglutamylation in acute megakaryocytic leukemia M7 ; compared to other subtypes of acute myelocytic leukemia. Leukemia. 1997; 11: 886-889. Rots MG, Pieters R, Jansen G, et al. A possible role for methotrexate in the treatment of childhood acute myeloid leukemia, in particular for acute monocytic leukemia. Eur J Cancer. 2001; 37: 492-498. Rots MG, Pieters R, Kaspers GJ, Veerman AJ, Peters GJ, Jansen G. Classification of ex vivo methotrexate resistance in acute lymphoblastic and myeloid leukaemia. Br J Haematol. 2000; 110: 791-800. Pui CH. Acute lymphoblastic leukemia in children. Curr Opin Oncol. 2000; 12: 3-12. Raimondi SC, Pui CH, Hancock ML, Behm FG, Filatov L, Rivera GK. Heterogeneity of hyperdiploid 51-67 ; childhood acute lymphoblastic leukemia. Leukemia. 1996; 10: 213-224. Ramakers-Van Woerden NL, Pieters R, Loonen AH, et al. TEL AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood. 2000; 96: 1094-1099. Bernstein J, Dastugue N, Haas OA, et al. Nineteen cases of the t 1; 22 ; p13; q13 ; acute megakaryoblastic leukaemia of infants children and a review of 39 cases: report from a t 1; 22 ; study group [letter]. Leukemia. 2000; 14: 216-218. Athale UH, Razzouk BI, Raimondi SC, et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood. 2001; 97: 3727-3732 and pennyroyal.

Pediatric alternative